Sokol ES - Search Results

1

Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.

Cannon TL, Randall JN BA, Sokol ES, Alexander SM, Wadlow RC, Winer AA, Barnett DM, Rayes DL BS, Nimeiri HS, McGregor KA. Cannon TL, et al. Among authors: sokol es. Cancer Treat Res Commun. 2022;32:100569. doi: 10.1016/j.ctarc.2022.100569. Epub 2022 Apr 30. Cancer Treat Res Commun. 2022. PMID: 35567913 Free article.

2

Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.

Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen MB, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom J, Alexander B, Brown C, Pusztai L, Ross JS, Ramkissoon SH. Huang RSP, et al. Oncologist. 2020 Nov;25(11):943-953. doi: 10.1634/theoncologist.2020-0449. Epub 2020 Sep 14. Oncologist. 2020. PMID: 32869930 Free PMC article.

3

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.

Sivapiragasam A, Ashok Kumar P, Sokol ES, Albacker LA, Killian JK, Ramkissoon SH, Huang RSP, Severson EA, Brown CA, Danziger N, McGregor K, Ross JS. Sivapiragasam A, et al. Among authors: sokol es. Cancer Med. 2021 Jan;10(1):53-61. doi: 10.1002/cam4.3550. Epub 2020 Dec 12. Cancer Med. 2021. PMID: 33314633 Free PMC article.

4

Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.

Huang RSP, Haberberger J, Sokol E, Schrock AB, Danziger N, Madison R, Trabucco S, Jin D, Pavlick D, Ramanan V, Hole K, McGregor K, Venstrom J, Ross JS. Huang RSP, et al. Int J Cancer. 2021 Apr 1;148(7):1778-1788. doi: 10.1002/ijc.33447. Epub 2020 Dec 23. Int J Cancer. 2021. PMID: 33336398

5

Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns.

Israel MA, Danziger N, McGregor KA, Murugesan K, Gjoerup O, Sokol ES, Tukachinsky H, Kurzrock R, Kato S, Sicklick JK, Nimeiri HS, Oxnard GR, Ross JS. Israel MA, et al. Among authors: sokol es. Oncologist. 2021 Sep;26(9):787-796. doi: 10.1002/onco.13844. Epub 2021 Jun 18. Oncologist. 2021. PMID: 34080753 Free PMC article.

6

Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.

Necchi A, Cucchiara V, Grivas P, Bratslavsky G, Jacob J, Spiess PE, Sokol ES, Killian JK, Lin D, Ramkissoon S, Huang RSP, Madison RW, Venstrom JM, Schrock AB, Danziger N, Decker B, Gjoerup O, Graf RP, Oxnard GR, Tukachinsky H, Ross JS. Necchi A, et al. Among authors: sokol es. Cancer. 2021 Dec 15;127(24):4557-4564. doi: 10.1002/cncr.33865. Epub 2021 Aug 11. Cancer. 2021. PMID: 34379803 Free article.

7

ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.

Akhoundova D, Hussung S, Sivakumar S, Töpfer A, Rechsteiner M, Kahraman A, Arnold F, Angst F, Britschgi C, Zoche M, Moch H, Weber A, Sokol E, Fritsch RM. Akhoundova D, et al. Int J Cancer. 2022 Dec 15;151(12):2161-2171. doi: 10.1002/ijc.34257. Epub 2022 Aug 30. Int J Cancer. 2022. PMID: 36053834 Free PMC article.

8

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.

Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, Ou FS, Ihuegbu N, Zill OA, Kabbarah O, Wang L, Bourgon R, de Sousa E Melo F, Bolen C, Daemen A, Venook AP, Innocenti F, Lenz HJ, Bais C. Johnson RM, et al. Nat Commun. 2022 Sep 19;13(1):5478. doi: 10.1038/s41467-022-33172-5. Nat Commun. 2022. PMID: 36117191 Free PMC article.

9

Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.

Ofir Dovrat T, Sokol E, Frampton G, Shachar E, Pelles S, Geva R, Wolf I. Ofir Dovrat T, et al. Cancer Biol Ther. 2018;19(10):871-874. doi: 10.1080/15384047.2018.1480289. Epub 2018 Jul 23. Cancer Biol Ther. 2018. PMID: 30036146 Free PMC article.

10

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M. Schrock AB, et al. Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134. Ann Oncol. 2019. PMID: 31038663 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page